Pacira BioSciences Inc (PCRX) can make a big difference with a little luck

With 0.57 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.51 million shares. The 52-week range on PCRX shows that it touched its highest point at $48.60 and its lowest point at $25.93 during that stretch. It currently has a 1-year price target of $45.30. Beta for the stock currently stands at 0.76.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of PCRX was down-trending over the past week, with a drop of -0.24%, but this was down by -2.31% over a month. Three-month performance dropped to -14.84% while six-month performance fell -5.86%. The stock lost -26.79% in the past year, while it has lost -13.40% so far this year. A look at the trailing 12-month EPS for PCRX yields 0.78 with Next year EPS estimates of 3.56. For the next quarter, that number is 0.65. This implies an EPS growth rate of 0.08% for this year and 26.54% for next year.

Float and Shares Shorts:

At present, 46.48 million PCRX shares are outstanding with a float of 45.16 million shares on hand for trading. On Mar 15, 2024, short shares totaled 4.07 million, which was 8.76% higher than short shares on Feb 15, 2024. In addition to CPRX as the firm’s Catalyst Pharmaceuticals, Inc., BCRX serves as its BioCryst Pharmaceuticals, Inc.

Institutional Ownership:

Through their ownership of 107.78% of PCRX’s outstanding shares, institutional investors have majority control over the company.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for PCRX since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential.

Dividends & Yield:

In terms of dividends, PCRX has a current ratio of $––, which is $–– over the trailing 12-months, while a dividend of $–– is likely to be paid on average over the next five years. Dividend yield is another indicator that appeals to many investors, and PCRX currently yields $0.00. In the past year, PCRX’s dividend yield has been $0.00, but when looking at the stock over the past five years, its yield has been $–. Accordingly, PCRX has a current buyback yield of $––. This was $–– for the TTM, and it was $–– for the past five years.